NASDAQ:NVAX Novavax Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $61.26 +4.11 (+7.19%) (As of 07/5/2022 01:51 PM ET) Add Compare Share Today's Range$55.74▼$62.4050-Day Range$36.28▼$62.7352-Week Range$34.88▼$277.80Volume134,817 shsAverage Volume7.11 million shsMarket Capitalization$4.79 billionP/E RatioN/ADividend YieldN/APrice Target$164.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Novavax MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside171.8% Upside$164.00 Price TargetShort InterestHealthy20.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.27Upright™ Environmental ScoreNews Sentiment0.32Based on 16 Articles This WeekInsider TradingN/AProj. Earnings Growth-61.70%From $27.23 to $10.43 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.19 out of 5 starsMedical Sector293rd out of 1,428 stocksBiological Products, Except Diagnostic Industry44th out of 218 stocks 3.3 Analyst's Opinion Consensus RatingNovavax has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $164.00, Novavax has a forecasted upside of 171.8% from its current price of $60.33.Amount of Analyst CoverageNovavax has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted20.13% of the outstanding shares of Novavax have been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novavax has recently increased by 30.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovavax has received a 76.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases ", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Novavax is -0.27. Previous Next 2.4 News and Social Media Coverage News SentimentNovavax has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Novavax this week, compared to 19 articles on an average week.Search Interest201 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows75 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 23% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Novavax is held by insiders.Percentage Held by Institutions43.91% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Novavax are expected to decrease by -61.70% in the coming year, from $27.23 to $10.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioNovavax has a PEG Ratio of 0.06. PEG Ratios below 1 indicate that a company could be undervalued. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Email Address About Novavax (NASDAQ:NVAX) StockNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Read More NVAX Stock News HeadlinesJuly 5, 2022 | investorplace.comWhy Is Novavax (NVAX) Stock Rallying Today?July 5, 2022 | americanbankingnews.comNovavax, Inc. (NASDAQ:NVAX) Sees Large Growth in Short InterestJuly 4, 2022 | cnet.comWhat to Know About NovavaxJuly 2, 2022 | nasdaq.comScared of Omicron BA.4/BA.5? Novavax Has a Vaccine for ThatJuly 2, 2022 | reuters.comNovavax expects COVID vaccine targeting Omicron in fourth quarterJuly 1, 2022 | investorplace.comWhy Is Novavax (NVAX) Stock Up 10% Today?July 1, 2022 | finance.yahoo.comIt's a Bear Market, but Is This Stock in Even More Trouble?July 1, 2022 | americanbankingnews.comNovavax (NASDAQ:NVAX) Shares Up 3.2%June 30, 2022 | finance.yahoo.comNovavax (NVAX) Stock Moves -0.81%: What You Should KnowJune 30, 2022 | finance.yahoo.com2 Risky Stocks That Could Continue Falling This YearJune 29, 2022 | investors.comVaccine Stocks: FDA Experts Recommend Adding Omicron To Covid Boosters - Investor's Business DailyJune 29, 2022 | seekingalpha.comNovavax says vaccine shows response vs variants as FDA panel votes for Omicron component - Seeking AlphaJune 29, 2022 | reuters.comTaiwan to receive first doses of Novavax COVID vaccine this week - Reuters.comJune 29, 2022 | cnbc.comFDA panel recommends changing Covid shots to fight omicron this fall - CNBCJune 28, 2022 | finance.yahoo.comNovavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants - Yahoo FinanceJune 27, 2022 | fool.com3 Reasons to Buy Novavax and 1 to Sell - The Motley FoolJune 27, 2022 | finance.yahoo.com3 Reasons to Buy Novavax and 1 to SellJune 24, 2022 | cnet.comWhat Is Novavax? - CNETJune 24, 2022 | americanbankingnews.comNovavax (NASDAQ:NVAX) Trading Up 3.9%June 23, 2022 | marketwatch.comNovavax: CHMP Recommends Expanded Europe Vaccine Authorization to Ages 12-17 - MarketWatchJune 23, 2022 | finance.yahoo.comNovavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17 - Yahoo FinanceJune 23, 2022 | reuters.comEMA recommends Novavax COVID vaccine for adolescentsJune 23, 2022 | reuters.comNovavax's COVID-19 shot authorized in Taiwan for adultsJune 23, 2022 | seekingalpha.comTaiwan gives emergency use approval to Novavax's COVID-19 vaccineJune 23, 2022 | finance.yahoo.comWhy Novavax Stock Is Soaring This WeekSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NVAX CUSIP67000210 CIK1000694 Webwww.novavax.com Phone(240) 268-2000Fax240-268-2100Employees1,541Year Founded1987Company Calendar Last Earnings5/09/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$164.00 High Stock Price Forecast$209.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+167.7%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($17.68) Trailing P/E RatioN/A Forward P/E Ratio2.25 P/E Growth0.06Net Income$-1,743,750,000.00 Net Margins-93.91% Pretax Margin-91.86% Return on Equity-572.54% Return on Assets-49.13% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio0.99 Sales & Book Value Annual Sales$1.15 billion Price / Sales4.18 Cash FlowN/A Price / Cash FlowN/A Book Value($4.65) per share Price / Book-13.17Miscellaneous Outstanding Shares78,140,000Free Float76,494,000Market Cap$4.79 billion OptionableOptionable Beta1.59 Social Links Novavax Frequently Asked Questions Should I buy or sell Novavax stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock. View analyst ratings for Novavax or view top-rated stocks. What is Novavax's stock price forecast for 2022? 8 brokers have issued 1-year price objectives for Novavax's stock. Their NVAX stock forecasts range from $35.00 to $209.00. On average, they predict Novavax's stock price to reach $164.00 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price. View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts. How has Novavax's stock performed in 2022? Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX stock has decreased by 57.7% and is now trading at $60.59. View the best growth stocks for 2022 here. When is Novavax's next earnings date? Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Novavax. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported $2.56 EPS for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company had revenue of $703.97 million for the quarter, compared to the consensus estimate of $845.20 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The firm's revenue for the quarter was up 57.4% on a year-over-year basis. During the same quarter last year, the company earned ($3.05) earnings per share. View Novavax's earnings history. When did Novavax's stock split? How did Novavax's stock split work? Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split. What guidance has Novavax issued on next quarter's earnings? Novavax issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion. Who are Novavax's key executives? Novavax's management team includes the following people: Mr. Stanley Charles Erck, Pres, CEO & Director (Age 74, Pay $1.12M)Mr. James Patrick Kelly C.F.A., Exec. VP, CFO & Treasurer (Age 56, Pay $355.23k)Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 56, Pay $657.8k) (LinkedIn Profile)Mr. John Joseph Trizzino B.S., M.B.A., Exec. VP and Chief Bus. & Commercial Officer (Age 62, Pay $636.85k)Dr. Gregory M. Glenn, Pres of R&D (Age 68, Pay $813.44k) (LinkedIn Profile)Mr. Richard P. Crowley, Exec. VP & COO (Age 65)Dr. Gale E. Smith, Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist (Age 72)Mr. Biegie Lee, Sr. VP & Chief Information OfficerMs. Silvia Taylor M.B.A., MBA, Sr. VP of Global Corp. Affairs & Investor RelationsMr. Troy Morgan Esq., J.D., Sr. VP & Chief Compliance Officer (Age 51) What is Stanley C. Erck's approval rating as Novavax's CEO? 46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees. Who are some of Novavax's key competitors? Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of NVAX's competitors. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE). What is Novavax's stock symbol? Novavax trades on the NASDAQ under the ticker symbol "NVAX." How do I buy shares of Novavax? Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Novavax's stock price today? One share of NVAX stock can currently be purchased for approximately $60.59. How much money does Novavax make? Novavax (NASDAQ:NVAX) has a market capitalization of $4.73 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.68) on an earnings per share basis. How many employees does Novavax have? Novavax employs 1,541 workers across the globe. When was Novavax founded? Novavax was founded in 1987. How can I contact Novavax? Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for Novavax is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100. This page (NASDAQ:NVAX) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here